Pharmacy and Wellness Review
Volume 6

Issue 1

Article 6

August 2014

Ramucirumab: A New Agent for Advanced or Metastatic Gastric
Junction Adenocarcinoma
Adam Smith
Ohio Northern University

Rebecca Worden
Ohio Northern University

Jessica Hoffert
Ohio Northern University

Brendon Rasor
Ohio Northern University

Hannah Stewart
Ohio Northern University

See next page for additional authors

Follow this and additional works at: https://digitalcommons.onu.edu/paw_review
Part of the Digestive System Diseases Commons, Gastroenterology Commons, Oncology Commons,
and the Pharmaceutics and Drug Design Commons
This Article is brought to you for free and open access by
the ONU Journals and Publications at
DigitalCommons@ONU. It has been accepted for
inclusion in Pharmacy and Wellness Review by an
authorized editor of DigitalCommons@ONU. For more
information, please contact digitalcommons@onu.edu.

Ramucirumab: A New Agent for Advanced or Metastatic Gastric Junction
Adenocarcinoma
Authors
Adam Smith, Rebecca Worden, Jessica Hoffert, Brendon Rasor, Hannah Stewart, and David Koh

This article is available in Pharmacy and Wellness Review: https://digitalcommons.onu.edu/paw_review/vol6/iss1/6

Oncology

Ramucirumab: A New Agent for Advanced or Metastatic
Gastric Junction Adenocarcinoma
Adam Smith, fifth-year pharmacy student from Dublin, Ohio; Rebecca Worden, fourth-year pharmacy student from
Middleton, Wis.; Jessica Hoffert, fourth-year nursing student from Shakopee, Minn.; Brendon Rasor, fourth-year pharmacy
student from Kettering, Ohio; Hannah Stewart, fifth-year pharmacy student from Brazil, Ind.; David Koh, R.Ph., Ph.D.,
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Abstract
Ramucirumab (Cyramza®), approved April 21, 2014, is a
vascular endothelial growth factor receptor 2 (VEGFR2) antagonist with a U.S. Food and Drug Administration (FDA)
indication for the treatment of advanced or metastatic gastric/gastroesophageal junction adenocarcinoma. Gastric cancer is a prevalent cancer in the United States with a poor
prognosis. The phase 3 trial, REGARD, shows that ramucirumab, when used within four months after the last dose of
first-line chemotherapy or six months after the last dose of
adjuvant chemotherapy, increases overall survival. Also,
ramucirumab has been included in combination therapy,
such as in the RAINBOW trial, which demonstrated its effectiveness in combination with paclitaxel as a second-line
treatment option. Notable adverse reactions to ramucirumab
are severe hypertension and injection site reactions. Because
it is a newer anticancer agent, ramucirumab's full potential
may not yet be recognized. Possible future uses of ramucirumab may include the treatment of other forms of cancer
or utilization as a first-line agent
Key Terms
Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic
Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Food and Drug Administration (U.S.); Hypertensaon;
Paclitaxel; Prognosis; Review Literature; Stomach Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2
Introduction/Epidemiology
Gastric cancer is one of the most prevalent cancers worldwide, and is currently the 14th most common form of cancer
in the United States.1.2 Adenocarcinoma-type gastric cancers
account for 90 to 95 percent of all gastric malignancies.
While gastric cancer is most commonly diagnosed in elderly
patients, excluding those cancers affecting the gastric cardia,
recent decades have revealed a nearly doubled incidence in
gastric cancer among U.S. patients between the ages of 25
and 36 years (0.27 up to 0.45 per 100,000 between 19771981 to 2002-2006, respectively). Recent incidence rates for
gastric adenocarcinomas involving the gastric cardia andl/or
gastroesophageal junction are around two and 1.94 per
100,000, respectively.2 The American Cancer Society projects
that in the United States there will be 22,220 new cases and
10,990 deaths due to gastric cancers for the year 2014.3
Gastric cancer is often difficult to detect until later stages of
development, and only 10 to 20 percent of cases are diagnosed in an early stage. Therefore, most patients do not present until the cancer has already metastasized.2,4 At best,
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five-year survival is typically around SO percent for cases
localized in distal regions of the stomach. Five-year survival
drops to almost 0 percent for nonlocalized distal cases and is
10 to 15 percent for cases involving proximal regions of the
stomach. Thus, it is recommended that high risk individuals
undergo routine screening to monitor for development of
gastric cancer.4
Known risk factors that contribute to the development of
gastric cancer include: age (most common between 60 and
80 years), male gender and a family history of gastric cancer.1.2 Lifestyle factors contributing to gastric cancer include
a diet low in fruits and vegetables and/or high in salted and
preserved foods, smoking and certain industrial occupations.
1•4 Gastric cancers also tend to be more prevalent among individuals of African, Asian and Native American descent.
Current treatments of gastric cancer include surgery,
radiotherapy, chemotherapy and, most recently, targeted
therapy.t.4 With utilization of first-line agents including fluoropyrimidine, platinum and surgery, there will still be over
10,000 deaths in the United States in 2014 directly caused by
gastric cancer. Consequently, new treatment options with
improved efficacy toward gastric cancer are needed. Trials of
drugs such as bevacizumab (a monoclonal antibody targeting
vascular endothelial growth factor A (VEGF-A) to inhibit angiogenesis) have been conducted to evaluate alternative
mechanisms to successfully treat gastric cancer and thus reduce mortality. Ramucirumab, a monoclonal antibody targeting the vascular endothelial growth factor receptor (VEGFR),
is the latest angiogenesis inhibitor that helps to increase the
survival rate of gastric cancer patients. This novel mechanism categorizes ramucirumab as targeted therapy, which
provides a new and unique treatment option for gastric cancer to prolong survival.

Pathophysiology
There is a well-documented correlation between Helicobacter pylori (H. pylori) infections and development of gastric
cancer.U These gram-negative bacteria are associated with
cases of severe and chronic gastritis as they secrete a
number of substances such as proteases, phospholipases,
ammonia, acetaldehyde and reactive oxygen species that are
capable of inducing histological and genetic changes. These
alterations lead to malignant cell growth in infected areas of
the stomach. This can initiate a cascade of histopathological
changes in gastric mucosa leading to the development of a
gastric malignancy, particularly in patients with genetic susceptibility and poor diet.
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Gastric adenocarcinoma presents in two histologically
distinct forms: intestinal and diffuse.1 Intestinal gastric adenocarcinomas form differentiated clusters of cohesive neoplastic cells that easily ulcerate. This type tends to have a
better prognosis and is more common in the elderly, males
and African Americans. It is also heavily influenced by environmental factors, including diet, H. pylori infections and
obesity. Diffuse gastric adenocarcinomas are not as differentiated and, instead, manifest as a generalized thickening of
the stomach wall. Diffuse-type is more common in females,
younger patients and may have a genetic predisposing factor
linked with type A blood. Advanced or invasive gastric adenocarcinomas develop along a cascade of histological changes.s Initially, atrophy of the stomach lining leads to changes
in the parietal cells, which is followed by intestinal metaplasia where the normal gastric cells begin to display an intestinal cell phenotype. Lastly, neoplastic intestinal dysplasia
develops and may lead to carcinoma in the affected area. This
cascade is more relevant to intestinal-type carcinomas versus diffuse-type.
The link to family history and the actions of H. pylori indicate
that a number of inherited and pathologically induced genetic changes can lead to the onset of gastric adenocarcinoma.1
Investigators have determined that, on average, 4.18 gene
changes are needed. Mutations in p27, p53, the K-ras oncogene and various cell signaling pathways are commonly seen.
More aggressive gastric adenocarcinomas also develop the
ability to express VEGF leading to an increased incidence of
metastasis.

Clinical Presentation
As previously mentioned, gastric adenocarcinomas are often
difficult to detect in early stages as patients are often asymptomatic.4 In approximately 50 percent of cases, patients present with minor symptoms, such as dyspepsia, which are
associated with a wide variety of gastrointestinal ailments.
Due to the lack of symptom manifestation, 80 percent to 90
percent of patients present with locally advanced or metastatic tumors and complain of anorexia and weight loss as
well as abdominal pain. Nausea and vomiting can occur with
obstructive tumors while ulcerated tumors may cause bleeding that leads to hematemesis, melena and gastrointestinal
hemorrhaging. Palpable masses, cachexia, bowel obstruction,
ascites, hepatomegaly and lower extremity edema can also
indicate advanced gastric adenocarcinoma. In these instances, the tumor has often already metastasized to neighboring
structures and/or lymph nodes.
Treatment
Surgical intervention is the p1imary means of treating gastric
adenocarcinomas.2 Given the high incidence of presentation
in advanced stages of the disease, surgery is often complemented with adjuvant radio- and/or chemotherapy. Surgery
can be performed for cases with a localized tumor in the
stomach and for cases limited to local node involvement.
Cases with distal node involvement or metastasis to other
structures outside the stomach often necessitate adjuvant or
neoadjuvant chemotherapy. Stage Ill patients require radical
surgery followed by chemoradiation therapy, while patients
Fall 2014 Volume 6, Issue 1
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presenting at stage IV typically receive intensive palliative
chemotherapy and radiotherapy.
Chemotherapeutic agents commonly used in the treatment
and palliation of gastric cancers include 5-tluorouracil
(5-FU), methotrexate, docetaxel and cisplatin.2 Methotrexate
and 5-FU are antimetabolites that disrupt normal deoxyribonucleic acid (DNA) synthesis while cisplatin is a platinumcontaining alkylating agent that acts to directly damage DNA.
Docetaxel is a taxane compound that interferes with mitosis.6
There are multiple standard combination protocols as well as
numerous clinical trials underway evaluating new combination protocols.2, 7 Recent progress in the development of targeted therapies has led to an increase in studies for potential
future treatments of a wide variety of cancers including
gastric. Several drugs showing significant promise in the
treatment of advanced gastric cancer include the monoclonal
antibodies trastuzumab (for HER-2 positive cancers) and
ramucirumab (anti-VEGFR2).8.9

Indications and Mechanism of Action
Ramucirumab is approved for the treatment of advanced or
metastatic gastric or gastroesophageal junction adenocarcinoma as a single agent.to This treatment regimen should be
used if disease progression occurs with or after tluoropyrimidine- or platinum-containing chemotherapy.11 Ramucirumab
is an antineoplastic agent and a recombinant monoclonal
antibody in the lgGl class.10,11 The drug binds to the vascular
endothelial growth factor receptor 2 (VEGFR2) with a high
affinity.11 By binding to the VEGFR2 receptor, ramucirumab
blocks the binding of VEGFR ligands, including VEGF-A,
VEGF-C, and VEGF-D, which inhibits the activation of the receptor. Ligand-induced proliferation and migration of endothelial cells are inhibited. Therefore, tumor vascularity and
growth are reduced. Ramucirumab does not affect initial levels ofVEGF ligands, unlike bevacizumab, another VEGF inhibitor (which binds to the ligand VEGF itself).12 By antagonizing
the receptor rather than binding the ligand, ramucirumab
may have less resistance.
Pharmacokinetics
Ramucirumab is given intravenously (IV) at a dose of
8mg/kg every two weeks.12 The half-life of ramucirumab at
steady-state is 200 to 300 hours and accumulates with increasing doses.12. 13 A phase 1 clinical trial conducted by
Spratlin and colleagues studied the pharmacokinetics and
pharmacodynamics of ramucirumab.13 Patients with advanced solid malignancies received escalating doses of ramucirumab as a one hour intravenous infusion. The clearance
rate of ramucirumab decreased disproportionately as the
dose was increased. This nonlinear effect suggests that the
drug is eliminated by saturable receptor-mediated clearance.12. 13 There have not yet been studies evaluating the effects of hepatic or renal impairment on the pharmacokinetics
of ramucirumab.12 The trial by Spratlin and colleagues also
showed that circulating VEGF-A concentrations increased
almost immediately after treatment to 1.5- to 3.5-fold higher
than pretreatment concentrations and remained elevated
until the next treatment.13 As long as ramucirumab was present, VEGF-A levels remained elevated. The soluble vascular
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endothelial growth factor receptors one and two (sVEGFR-1
and sVEGFR-2) concentrations tended to decrease immediately after ramucirumab was administered, but they recovered to near-pretreatment levels. Neither the VEGF-A,
sVEGFR-1 or sVEGFR-2 levels were related to the dose of
ramucirumab. The pharmacokinetic profile of ramucirumab
suggests that weekly dose administrations of the drug are
biologically relevant The minimum target trough level was
selected to be greater than or equal to 20 µg/mL basedl on
the pharmacodynamic and efficacy data gathered from human tumor xenografts implanted in mice. This trough level
was achieved in all the treated patients from this trial.
Adverse Events/Toxicity
The most prevalent adverse events observed in patients
were hypertension, diarrhea, anemia and infusion-related
reactions.11 Hypertension occurred in 16 percent of patients
with 8 percent of patients experiencing grade 3 or 4, which is
classified as severe with a blood pressure reading of greater
than or equal to 180/llOmm Hg (versus a grade 1 or 2,
which is considered mild to moderate with a blood pressure
reading of 140 to 179/90 to 109mm Hg).11· 14 The current
recommendation is to temporarily stop the infusion until the
hypertension is controlled with antihypertensive medication
or to permanently discontinue ramucirumab infusion if the
hypertension is severe and uncontrolled.11 The infusion reactions associated with ramucirumab, which usually occur with
the first or second infusion, include chills, flushing, hypotension, bronchospasm, dyspnea, hypoxia, wheezing, chest pain
or tightness, supraventricular tachycardia, back pain or
spasms, rigors or tremors, and paresthesia. Patients should
be continuously monitored for infusion reaction symptoms
and the treatment should be immediately and permanently
discontinued for grade 3 or 4 reactions. Ramucirumab was
shown to increase the risk of hemorrhage, including cases of
severe and fatal bleeding. Consequently, in the United States,
a black box warning for ramucirumab exists, which states
that it should be permanently discontinued in patients who
experience serious hemorrhagic events. Other serious adverse events that have occurred in patients receiving ramucirumab include arterial thrombotic events, gastrointestinal
perforation, and reversible posterior leukoencephalopathy
syndrome, which causes lesions in the parieto-occipital regions of the cerebral hemispheres and is characterized by
altered mental status, headache, seizure and visual disturbances.11.1s If any of these events occur, it is recommended to
discontinue treatment.11 Wound healing impairment is commonly seen in patients who are receiving antiangiogenic
therapy; however, ramucirumab has not yet been studied in
patients with serious or nonhealing wounds. It is recommended to stop treatment prior to, during and after treatment of such wounds and to continue ramucirumab infusions
only when the wound is fully healed.
Drug interaction studies have not yet been conducted with
ramucirumab. However, based on its therapeutic category,
there are several drugs that should be avoided while on
ramucirumab.12 Monoclonal antibodies have been shown to
enhance adverse and toxic effects of belimumab, an IgGllambda monoclonal antibody that blocks binding of soluble
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human B lymphocyte stimulator protein to receptors on B
lymphocytes (and therefore preventing the survival of B lymphocytes), so it has a risk factor of X (avoid combination with
ramucirumab).11•1 6The adverse and toxic effects of bisphosphonate derivatives such as alendronate and ibandronate
may be enhanced by systemic angiogenesis inhibitors, which
gives them a risk factor of C (monitor therapy when used
with ramucirumab).
REGARD Trial: Patient survival rate
Ramucirumab monotherapy for previously treated advanced
gastric or gastroesophageal junction adenocarcinoma was
evaluated in an international randomized, multicenter, placebo-controlled, phase 3 trial.17 Also known as REGARD, this is
the trial that led to the FDA approval of ramucirumab. The
purpose of the trial was to quantify the advantage in survival
rate in patients who received ramucirumab versus those who
did not With a sample size of 355 patients and a 2:1 ratio of
those who received ramucirumab versus placebo, there was
an increased median overall survival rate in those receiving
ramucirumab of 5.2 months versus 3.8 months for the placebo group. The study was conducted as a double-blind, randomized placebo-controlled trial in 29 countries all across
the world. Inclusion criteria for the study gathered patients
ages 24 to 87 with gastric adenocarcinoma, disease progression within the past four months of prior treatment, and an
eastern cooperative oncology group (ECOG; see Table 1) performance score of 0 or 1.u.1s Exclusion criteria included
grade 3 or higher gastrointestinal (GI) bleeding within three
months of randomization, arterial thromboembolic events
within six months of randomization and uncontrolled hypertension.17 All parties involved were masked except for in
emergencies only. Every patient received recommended supportive care, excluding any additional investigational drugs,
and received ramucirumab or placebo until confirmed disease progression, intolerable toxicity or death. The primary
measure within the study was overall survival rate. Secondary measures included rates of adverse effects and progression-free intervals. Tumor and quality of life assessments
were also obtained. Results of the study concluded that
ramucirumab therapy was superior to placebo therapy. Not
only did the study conclude that the drug increased the overall survival rate, but also that the risk of death and disease
progression were reduced between the two groups. These
results, along with ramucirumab's unique mechanism of action compared to other drugs used to treat gastric cancer,
prompted the indication for second-line treatment of gastric
or gastroesophageal adenocarcinoma. When overall survival
rates with ramucirumab therapy were compared to those of
bevacizumab (a monoclonal antibody targeting VEFG-A),
bevacizumab had slightly better rates, which was deemed to
be statistically insignificant.
RAINBOW Trial: Combination Therapy
A double-blind, randomized phase 3 trial, ramucirumab plus
placlitaxel versus placebo plus paclitaxel in patients with
previously treated advanced gastric or gastroesophageal
junction adenocarcinoma, was conducted by Wilke and colleagues.19 Also known as the RAINBOW trial, this study evaluated the effects of ramucirumab in combination with
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Table 1. Eastern Cooperative Oncology Group (ECOG) Performance Scale.
Grade

ECOG

0

Fully active, able to carry on all pre-disease performance without restriction.

1

Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary
nature; e.g., light housework, office work

2

Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50%
of waking hours.

3

Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.

4

Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.

5

Dead.

As published in Am. J. Clin. Oncol.: Oken, M.M., Creech, R.H., Tormey, D.C., Horton, ]., Davis, T.E., McFadden, E.T., Carbone, P.P.:
Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am f Clin Oneal 5:649-655, 1982.
The ECOG Performance Status is in the public domain and therefore available for public use. To duplicate the scale, please
cite the reference above and credit the Eastern Cooperative Oncology Group, Robert Comis M.D., Group Chair.
paclitaxel in patients with previously treated advanced gastric cancer. The objective of the study was to determine if
overall survival rate increased in patients treated with ramucirumab plus paclitaxel versus placebo plus paclitaxel. In ithis
placebo-controlled, multicentered phase 3 trial, patients who
had disease progression within four months after platinum
plus fluoropyrimidine with or without an anthracycline as a
first-line chemotherapy treatment were eligible for the trial.
Patients were randomized to receive either 8mg/kg of ramucirumab or a placebo intravenously on days 1 and 15, and
both groups received paclitaxel 80mg/m2 intravenously on
days 1, 8 and 15 of a 28-day cycle. The primary endpoint was
overall survival of the patients. The overall survival rate
among the patients in the ramucirumab plus paclitaxel group
was significantly higher than in the control group, with median survival periods of 9.6 and 7.4 months, respectively. Further, the 12-month overall survival rate was 40 percent in
the ramucirumab group and 30 percent in the control group.
Taken together, the findings suggest that this combination
therapy could become a new standard second-line treatment
for patients with advanced gastric cancer. In addition, although this particular study is complete, 13 patients in the
ramucirumab plus paclitaxel group and seven in the control
group are continuing to receive their respective treatments
in order to evaluate an extension phase of the study to determine the long-term results of the treatments.

Standard dosing of ramucirumab is 8mg/kg every two
weeks.20 This should continue unless the disease progresses
or there is evidence of unacceptable toxicity. Before administering ramucirumab, pre-medicate the patient with an Hl
antagonist such as diphenhydramine. If the patient has experienced a grade 1 or 2 reaction previously, also medicate
with dexamethasone and acetaminophen before ramucirumab is initiated. The patient should be pre-medicated at
an appropriate interval prior to administering ramucirumab
in order to ensure optimal patient comfort and tolerance level. Diphenhydramine may only take five minutes to take
effect if given JV, but up to two hours if taken orally. Similarly, dexamethasone should be administered anywhere from
15 to 30 minutes before treatment initiation, and acetaminophen can be administered five to 10 minutes before.11

Handling of Ramucirumab
Vials of ramucirumab are supplied in a concentration of
10mg/ml, and the calculated dose should be diluted with
normal saline.2° Ramucirumab is not stable in solutions containing dextrose. The mixture should be inverted to ensure
even displacement in a final volume of 250mL. Ramucirumab
should be stored under refrigeration at a temperature

The infusion itself takes place over 60 minutes through a
single infusion line. Ramucirumab should not be infused in
the same IV line as electrolytes or other medications, and
should not be given as an IV push.20 During administration, it
is important to monitor for any infusion reactions: signs of
tremors, back pain, chest pain and tightness, chills, flushing,
dyspnea, hypoxia and paresthesia. More serious cases of in-
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between 2 degrees and 8 degrees Celsius (36 degrees to 46
degrees Fahrenheit). The diluted mixture should be stored
no longer than 24 hours. When preparing ramucirumab, it is
important to ensure quality by inspecting vials for any discoloration or loose particles.21 If present, discard the vial immediately. Any unused ramucirumab, as well as supplies used
for preparation and administration, and any patient or
equipment waste, should be discarded in indicated yellow
chemotherapy bins for incineration or according to company
policy.
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fusion reactions include bronchospasms, hypotension and
supraventricular tachycardia. Close monitoring is required at
every administration of ramucirumab as the incidence of
infusion-related reactions is slightly more prevalent in the
first or second administration but presents a risk throughout
treatment. If a grade 1 or 2 infusion reaction occurs, reduce
the infusion rate by 50 percent and continue treatment. If a
grade 3 or 4 reaction presents itself, permanently discontinue ramucirumab.11
Safety for Health Care Professionals
While the effects of ramucirumab on patients are documented, the effects on those who prepare, administer and dispose
of the drug are not Occupational exposure to hazardous
drugs, namely chemotherapy, are highest in pharmacists
during its preparation and nurses during its administration.21 Lack of chemotherapy precautions at any stage of drug
handling can result in hair loss, contact dermatitis and skin
injury in the short term, as well as a higher rate of genotoxicity, cancer, fetal Joss and infertility in the long term. Appropriate precautions include the use of specific safety cabinets
for preparation and appropriate personal protective equipment (PPE). For preparation, this includes a ventilated cabinet that takes both employee safety and product sterility into
account, which includes proper disposal of vapors and air
circulation. Further precautions include wearing two pairs of
chemotherapy-tested gloves to safeguard the preparer
against any potential contact with the drug or waste
contents, a chemotherapy-tested gown and a face shield or
respirator if there is any risk of inhalation or splattering of
chemotherapy agents. These same necessities carry to the
bedside when nurses administer antineoplastic agents including further precautions such as using needleless systems
and ensuring that IV tubing is primed with normal saJine or a
nonhazardous drug by a pharmacist prior to patient administration. Identical precautions are needed in order to dispose of bodily fluids from a patient receiving chemotherapy,
in addition to placing an absorbent pad over the toilet w!hen
flushing in order to prevent splashing and contact.22 Disposal
of any equipment used in the administration of ramucirumab
or care of a patient receiving treatment should be placed in a
biohazard bag and be placed in a yellow chemotherapy bin
for incineration. This includes absorbent pads, IV tubing and
any PPE. Any sharps or needles used in administration or
maintenance of ramucirumab should be placed in a specified
chemotherapy sharps container for proper disposal and incineration.21 These precautions should persist after the inmal
treatment, as chemotherapy and other hazardous drugs
remain in the patient's body for up to 48 hours and are subsequently excreted through waste such as urine, stool and
emesis. Education on similar precautions, as well as disposal
methods, should be provided to the family and caregivers of
those on chemotherapy in order to prevent any accidental
exposure.22
Management of Adverse Effects
As stated earlier, hypertension is one of the most clinically
significant adverse effects of ramucirumab.11 Any existing
hypertension should be well-controlled before treatment is
initiated, and blood pressure should be monitored starting
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two weeks prior to infusion initiation and continued every
two weeks throughout the course of therapy. More frequent
monitoring may be indicated if the patient has a history of
hypertension or if the patient develops hypertension over
the course of ramucirumab administration.20 If a hypertensive crisis occurs, immediate medical intervention, such as
nitroprusside administration, may be indicated, although
side effects must also be monitored.23 Educating patients on
measuring their blood pressure at home may help prevent a
hypertensive crisis from occurring. It is also important to
ensure that patients are aware of side effects, such as flushing. headaches and heart palpitations, which may indicate a
hypertensive crisis. This knowledge, as well as health care
provider contact information, may help patients avoid a crisis and follow a medication regimen that effectively controls
their blood pressure. Education on medication compliance,
as well as lifestyle modifications, may provide additional
benefit over the course of treatment.
The incidence of bleeding and hemorrhage risk in those
taking ramucirumab is slightly increased over those who
received a placebo.20 A proactive approach to this adverse
effect is prevention and, consequently, the use of bleeding
precaution procedures should be followed in both the health
care setting and as the patient is discharged. This involves
avoiding unnecessary invasive procedures, such as rectal
temperatures. In addition, the use of small gauge needles and
direct pressure on bleeding sites for up to five minutes may
help with clotting.23 Monitoring blood counts for abnormal
values in platelets or prothrombin time, as well as hemoglobin and hematocrit values that may indicate an internal
bleed, is crucial. Observing trends in vital signs while the patient is in the hospital to monitor for signs of tachycardia and
hypotension may alert health care providers to any potential
hypovolemia indicating the presence of an internal bleed.
Related to personal hygiene, soft toothbrushes and safety
razors should be used. Any sharp corners that may cause
bleeding should be covered in padding. Patients should receive education on providing these safety measures at home,
as well as observing for abnormal bruising or feelings of dizziness and heart palpitations. Patients should be instructed
to immediately report to their health care provider if they
notice any of these symptoms.
Cancer-related fatigue (CRF), while comparable among the
treatment modalities, still affects 36 percent of patients on
ramucirumab.23 Cancer-related fatigue is defined by Horneber et al. as "the syndrome of fatigue and exhaustion in cancer patients."24 This syndrome affects all aspects of health
and manifests itself not only by a Jack of energy, but also by a
loss of drive and social withdrawal in addition to impaired
concentration and memory Joss. Many of these symptoms are
subjective and can be identified by thorough communication
between the patient and the health care provider. Symptoms
may not be directly observed due to a focus on the treatment
modality of the cancer itself, or they may not be reported if
the patient withholds information due to fear of judgment or
delay in treatment A degree of patient trust, as well as constant follow-up, may help providers to diagnose CRF more
readily and, consequently, facilitate initiation of appropriate
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treatment. Of all the side effects that accompany cancer patients undergoing treatment, CRF is considered the worst
due to its severe debilitation on the patient's quality of life. It
can occur at any stage of the disease process including after
admission. Proper education on CRF as a condition is imperative for treatment as patients who recognize the symptoms
are more open to treatment options.
While pharmacological components such as hematopoietic
growth factors and corticosteroids may improve CRF, they
are only effective for a minority of patients and are often a
short-term solution with added risks. However, nonpharmacologic activities such as physical exercise may provide the
same benefits without as many of the risks. In a metaanalysis completed by McMillan and Newhouse, it was shown
that all modes of physical activity, especially aerobic exercise, and to a lesser degree resistance exercise, may help not
only decrease the manifestations of CRF, but also the symptom clusters that accompany it such as depression and anxiety.2s Improvement in cardiac reserve, lung ventilation and
perfusion may explain such changes, especially since such
characteristics are diminished in cancer patients both during
and after treatment.
Conclusion

Gastric cancer is a prevalent disease that has a very low
survival rate once it becomes advanced or metastatic. Once
disease progression has led to metastasis, survival rates significantly drop despite the utilization of first-line therapies.
Ramucirumab is a monoclonal antibody that targets VEGF
receptors and is used for the treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma as
a single agent. Through studies such as REGARD and RAINBOW, ramucirumab has been shown to be an effective secondline therapy as monotherapy or combination therapy with
paclitaxel in prolonging survival over placebo. Ramucirumab
is a novel anticancer agent, as treatment with this agent is
categorized as "targeted therapy." However, its application in
other types of cancer should also be considered. Because of
the efficacy demonstrated by ramucirumab, it is crucial for
health care professionals to properly manage adverse effects,
such as hypertension and hemorrhage, to allow continuation
and success of ramucirumab therapy in the treatment of gastric or gastroesophageal junction adenocarcinoma.
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